RecruitingPhase 2NCT04423185

PLATFORM Study of Precision Medicine for Rare Tumors

Studying Rare neoplastic disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator: Ning Li, Doctor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Intervention: Almonertinib 110 MG(drug)
Enrollment: 770 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2028

Study locations (1)

Cancer hospital Chinese Academy of Medical Sciences, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04423185 on ClinicalTrials.gov

Other trials for Rare neoplastic disease

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07147465
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
Assistance Publique - Hôpitaux de Paris

See all trials for Rare neoplastic disease →

← Back to all trials